Express Pharma

Strong performance in US market to support Indian pharma’s growth in FY2024: ICRA

Revenues of ICRA’s sample set of companies to expand by 9-11 per cent in FY2024, OPM to improve by 150-200 bps to 22-23 per cent in FY2024

0 139